MIRA Pharmaceuticals, Inc. (MIRA)
MIRA moved a median of -0.90% 30 minutes after news, and -1.43% by the close. How MIRA actually reacts to news — the realized, point-in-time move the market made, measured across 207 labeled events over the last three years with zero look-ahead.
MIRA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.52% | 38% | 204 |
| 30-min | -0.90% | 36% | 207 |
| 60-min | -1.37% | 35% | 207 |
| to close | -1.43% | 40% | 198 |
| Middle 50% of MIRA reactions | -3.64% to +1.21% |
|---|---|
| Median reaction (30-min) | -0.90% |
| Measured reactions | 207 |
Half of all MIRA Pharmaceuticals, Inc. news events land between -3.64% and +1.21% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MIRA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MIRA's baseline. Nothing else.
Recent MIRA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +4.01% | |
| MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review | Press release | GlobeNewswire | +0.59% | +4.01% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +4.01% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -2.53% | +16.22% | |
| MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND | Press release | GlobeNewswire | -2.53% | +16.22% | |
| Form 10-Q MIRA PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.51% | +2.75% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.90% | -2.84% | |
| MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 | Press release | GlobeNewswire | -3.90% | -2.84% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -21.04% | |
| MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies | Press release | GlobeNewswire | +5.52% | -3.96% | |
| Form DEF 14A MIRA PHARMACEUTICALS, For: Jul 28 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.14% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | -2.68% | |
| MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain | Press release | ACCESS Newswire | -1.33% | -2.68% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +1.97% | +1.58% | |
| MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction | Press release | ACCESS Newswire | +1.97% | +1.58% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -1.34% | |
| MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC | Press release | ACCESS Newswire | +0.17% | -1.34% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +0.84% | |
| MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy | Press release | ACCESS Newswire | +1.04% | +0.84% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.33% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.97% | +4.95% | |
| MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 | Press release | ACCESS Newswire | +2.97% | +4.95% | |
| Form 8-K MIRA PHARMACEUTICALS, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | +17.86% | |
| MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN | Press release | ACCESS Newswire | +1.14% | +17.86% | |
| Form 10-Q MIRA PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.40% | |
| MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 | Press release | ACCESS Newswire | +3.68% | +2.64% | |
| Form 8-K MIRA PHARMACEUTICALS, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.29% | -1.42% | |
| Form 8-K MIRA PHARMACEUTICALS, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +3.68% | +2.64% | |
| MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate | Press release | ACCESS Newswire | -0.29% | -1.42% | |
| Form 10-K MIRA PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +0.00% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | +19.68% | |
| MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies | Press release | ACCESS Newswire | +0.88% | +19.68% | |
| MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 | Press release | ACCESS Newswire | -2.02% | -1.61% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -2.02% | -1.61% | |
| MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study | Press release | ACCESS Newswire | +0.82% | -2.46% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | -2.46% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -3.68% | -5.52% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | -2.04% | -2.04% | |
| Form 10-Q MIRA PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.30% | — | |
| MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | Press release | ACCESS Newswire | -1.34% | -5.66% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -1.34% | -5.66% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +4.71% | -4.71% | |
| MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain | Press release | ACCESS Newswire | -5.99% | -23.08% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -5.99% | -23.08% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.26% | |
| MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction | Press release | ACCESS Newswire | +0.00% | +2.26% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -2.25% | +3.91% | |
| MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog | Press release | ACCESS Newswire | -2.25% | +3.91% | |
| MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals | Press release | ACCESS Newswire | -4.41% | -5.07% | |
| Form 8-K MIRA PHARMACEUTICALS, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -4.41% | -5.07% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MIRA section they belong to.
Where else MIRA is measured.
MIRA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MIRA Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled MIRA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 207 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of MIRA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MIRA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.